SepsiCare | A disruptive multi-sensor chip for fast and effective management of Sepsis at the point of Care

Summary
SepsiCare project, aims at developing a profitable and scalable business based on SepsiCare integrated biosensors. SepsiCare is an integrated biochip that is capable to provide a set of key patient-condition indicators to the clinician in order to diagnose sepsis, monitor disease progression and assess the effects of treatment within minutes. The SepsiCare device integrates multiple highly sensitive photonic sensors on a low cost 20x20 mm2 semiconductor chip that is configured to quantify a panel of sepsis related biomarkers from small volumes of patient whole blood. What differentiates SepsiCare from the competition is that it offers a multi-sensor test to quantify multiple parameters that indicate sepsis, identify bacteria and guide therapy with high accuracy (concentrations of pg/mL) and at an affordable price (12 Euro per chip). Sepsis affects more than 30 million people worldwide each year and takes 8 million lives including more than 3 million children, translating into healthcare yearly costs nearly $24 billion in the US alone. Starting appropriate and effective antimicrobial treatment is crucial for sepsis survival. Previous reports have shown that the chance of survival drops by 7.6% each hour of disease progression until an appropriate antimicrobial treatment is started. Therefore, achieving an early and accurate diagnosis is a prerequisite for rapid and successful antibiotic therapy. However, point of care (POC) solutions for fast, affordable and effective management of sepsis remains a challenge. The impact of this unmet clinical need to the hospitals relates to the increased time & cost of patient hospitalization (~€30K per sepsis patient). For patients, this has an impact on increased mortality and morbidity (1 in 3 patients of sepsis die) resulting from suboptimal treatment of bacterial infections. By treating just 25% of sepsis patients on time using SepsiCare, a hospital saves up to €1M per year.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/888337
Start date: 01-01-2020
End date: 31-08-2020
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

SepsiCare project, aims at developing a profitable and scalable business based on SepsiCare integrated biosensors. SepsiCare is an integrated biochip that is capable to provide a set of key patient-condition indicators to the clinician in order to diagnose sepsis, monitor disease progression and assess the effects of treatment within minutes. The SepsiCare device integrates multiple highly sensitive photonic sensors on a low cost 20x20 mm2 semiconductor chip that is configured to quantify a panel of sepsis related biomarkers from small volumes of patient whole blood. What differentiates SepsiCare from the competition is that it offers a multi-sensor test to quantify multiple parameters that indicate sepsis, identify bacteria and guide therapy with high accuracy (concentrations of pg/mL) and at an affordable price (12 Euro per chip). Sepsis affects more than 30 million people worldwide each year and takes 8 million lives including more than 3 million children, translating into healthcare yearly costs nearly $24 billion in the US alone. Starting appropriate and effective antimicrobial treatment is crucial for sepsis survival. Previous reports have shown that the chance of survival drops by 7.6% each hour of disease progression until an appropriate antimicrobial treatment is started. Therefore, achieving an early and accurate diagnosis is a prerequisite for rapid and successful antibiotic therapy. However, point of care (POC) solutions for fast, affordable and effective management of sepsis remains a challenge. The impact of this unmet clinical need to the hospitals relates to the increased time & cost of patient hospitalization (~€30K per sepsis patient). For patients, this has an impact on increased mortality and morbidity (1 in 3 patients of sepsis die) resulting from suboptimal treatment of bacterial infections. By treating just 25% of sepsis patients on time using SepsiCare, a hospital saves up to €1M per year.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
EU-Programme-Call
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1